Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
Go back to Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals| ARROWHEAD RESEARCH (NASDAQ: ARWR) | Delayed: 80.65 +0.75 (0.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $79.90 | 52 Week High | $8.22 | |||
| Open | $80.72 | 52 Week Low | $3.07 | |||
| Day High | $82.84 | P/E | N/A | |||
| Day Low | $80.48 | EPS | $-1.30 | |||
| Volume | 1,131,522 | |||||
| (NASDAQ: MDGL) | Delayed: 519.80 +6.37 (1.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $513.43 | 52 Week High | $18.24 | |||
| Open | $516.83 | 52 Week Low | $6.60 | |||
| Day High | $527.71 | P/E | N/A | |||
| Day Low | $515.00 | EPS | $0.00 | |||
| Volume | 250,087 | |||||
